/TRDA

TRDA Stock - Entrada Therapeutics, Inc.

Q: What is the analyst price target for TRDA?

Analyst price target information is not currently available for TRDA.

Q: What is TRDA's market cap?

Market capitalization information is not currently available for TRDA.

Healthcare|Biotechnology|NASDAQ

$10.98+0.18%

+$0.02 (+0.18%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+18.4%upside

Target: $13.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TRDA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.12

52W High$18.76

52W Low$4.93

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$210.78M	$129.01M	N/A	N/A	N/A
Gross Profit	$210.78M	$129.01M	N/A	N/A	$-326,000
Gross Margin	100.0%	100.0%	N/A	N/A	N/A
Operating Income	$47.01M	$-3,162,000	$-97,248,000	$-51,127,000	$-26,667,000
Net Income	$65.63M	$-6,685,000	$-94,616,000	$-51,158,000	$-26,523,000
Net Margin	31.1%	-5.2%	N/A	N/A	N/A
EPS	$1.76	$-0.20	$-2.79	$-1.60	$-0.84

Company Overview

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

3 Bullish0 Neutral/Bearish

Price Targets

$25

Average Target

↑ 130.7% Upside

Now

$22

Low

$25

Average

$29

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 6th 2024	ROTH MKM	Initiation	Buy	$29
January 5th 2024	Oppenheimer	Initiation	Outperform	$22
April 3rd 2023	H.C. Wainwright	Initiation	Buy	$25

Earnings History & Surprises

TRDA

Beat Rate

53%

Last 17 quarters

Avg Surprise

+18.3%

EPS vs Estimate

Beats / Misses

9/8

Last 12 quarters

Latest EPS

$-1.06

Q4 2025

EPS Surprise History

Q1 24

-314.3%

$-0.29vs$-0.07

Q2 24

+215.3%

$0.68vs$-0.59

Q3 24

+1007.1%

$1.55vs$0.14

Q4 24

+47.8%

$-0.35vs$-0.67

Q1 25

+104.5%

$0.03vs$-0.66

Q2 25

+46.2%

$-0.42vs$-0.78

Q3 25

-20.9%

$-1.04vs$-0.86

Q4 25

-1.9%

$-1.06vs$-1.04

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 26, 2026	$-1.06	—	—	—
Q4 2025	Nov 6, 2025	$-1.04	$-1.06	-1.9%	✗ MISS
Q3 2025	Aug 6, 2025	$-0.86	$-1.04	-20.9%	✗ MISS
Q2 2025	May 8, 2025	$-0.78	$-0.42	+46.2%	✓ BEAT
Q1 2025	Feb 27, 2025	$-0.66	$0.03	+104.5%	✓ BEAT
Q4 2024	Nov 5, 2024	$-0.67	$-0.35	+47.8%	✓ BEAT
Q3 2024	Aug 13, 2024	$0.14	$1.55	+1007.1%	✓ BEAT
Q2 2024	May 7, 2024	$-0.59	$0.68	+215.3%	✓ BEAT
Q1 2024	Mar 13, 2024	$-0.07	$-0.29	-314.3%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.74	$1.02	+237.8%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.43	$-0.78	-81.4%	✗ MISS
Q2 2023	May 10, 2023	$-0.77	$-0.21	+72.7%	✓ BEAT
Q1 2023	Mar 6, 2023	$-0.84	$-0.79	+6.0%	✓ BEAT
Q4 2022	Nov 7, 2022	$-0.76	$-0.80	-5.3%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.72	$-0.74	-2.8%	✗ MISS
Q2 2022	May 12, 2022	$-0.65	$-0.69	-6.2%	✗ MISS
Q1 2022	Mar 15, 2022	$-1.28	$-0.89	+30.5%	✓ BEAT
Q4 2021	Dec 9, 2021	$-0.87	$-9.78	-1024.1%	✗ MISS
Q4 2021	Nov 1, 2021	—	$-0.48	—	—

Frequently Asked Questions about TRDA

What is TRDA's current stock price?

Entrada Therapeutics, Inc. (TRDA) is currently trading at $10.98 per share. The stock has moved +0.18% today.

What is the analyst price target for TRDA?

The average analyst price target for TRDA is $13.00, based on 1 analyst.

What sector is Entrada Therapeutics, Inc. in?

Entrada Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is TRDA's market cap?

Entrada Therapeutics, Inc. has a market capitalization of $0.42 billion, making it a small-cap company.

Does TRDA pay dividends?

No, Entrada Therapeutics, Inc. does not currently pay a dividend to shareholders.